IP Library › Granted Patent US 12,286,655
Granted Patent B2
US 12,286,655 · App. 17/814,371 · Granted Apr 29, 2025

Human alpha-galactosidase variants

Inventors: William Casey Hallows (San Francisco, CA); Kristen Jean Vallieu (Las Vegas, NV); Nikki Dellas (San Carlos, CA); Yu Zhu (Newark, CA); Judy Victoria Antonio Viduya (Greenbrae, CA); Chinping Chng (Menlo Park, CA); Antoinette Sero (Foster City, CA); Gjalt W. Huisman (Redwood City, CA); Rachel Cathleen Botham (Burlingame, CA); Moulay Hicham Alaoui Ismaili (San Mateo, CA)
Assignee: Crosswalk Therapeutics, Inc.
C12N9/2465C12N15/52C12N15/85A61K38/00C12N2015/8518C12Y302/01022
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,286,655
App. No.
17/814,371
Filed
Jul 22, 2022
Granted
Apr 29, 2025
Kind
B2
Art Unit
1656
USPC
424/94.61
Abstract

The present invention provides engineered human alpha-galactosidase polypeptides and compositions thereof. The engineered human alpha-galactosidase polypeptides have been optimized to provide improved thermostability, serum stability, improved cellular uptake, stability under both acidic (pH<4) and basic (pH>7) conditions, reduced immunogenicity, and improved globotriaosylceramide removal from cells. The invention also relates to the use of the compositions comprising the engineered human alpha-galactosidase polypeptides for therapeutic purposes.

Claims (24)

1. A recombinant polynucleotide comprising a polynucleotide sequence encoding a recombinant alpha galactosidase A comprising an amino acid sequence that has at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 158, wherein said amino acid sequence of said recombinant alpha galactosidase A comprises a glycine (G) at the position corresponding to residue 333 of SEQ ID NO: 158, and wherein said encoded recombinant alpha galactosidase A has alpha galactosidase A activity.

2. The recombinant polynucleotide of claim 1 , wherein said amino acid sequence of said encoded recombinant alpha galactosidase A further comprises at least one additional substitution or substitution set at one or more of positions 24/202, 39/47, 39/47/217, 39/151, 39/282/337/398, 39/337/343/398, 39/393/398, 47/130, 47/151, 47/343/345/393, 48, 48/68, 48/68/217/391/393, 48/217, 48/345/393, 48/393, 59/143, 68, 68/345, 130, 130/158, 130/158/393, 130/345/393, 143/271, 143, 143/387, 151, 151/158/217/343/345/393, 151/206/282/337/343/345/398, 151/282/393, 151/345/393/398, 151/393, 158, 158/393, 202, 206, 206/217, 217, 217/337/345/398, 271, 282/393, 345, 337/343/345/398, 343, 343/345/393/398, 393, or 393/398, wherein the amino acid position(s) correspond to the amino acid sequence of SEQ ID NO: 158.

3. The recombinant polynucleotide of claim 1 , wherein said amino acid sequence of said encoded recombinant alpha galactosidase A further comprises at least one substitution or substitution set 24S/202N, 39V/47D, 39V/47V/217K, 39V/151L, 39V/282N/337R/398A, 39V/337R/343G/398A, 39V/393V/398A, 47V/130E, 47V/151L, 47V/343D/345Q/393V, 48D, 48D/68E, 48D/217K, 48D/345Q/393V, 48D/393V, 59A/143S, 68E, 68E/345Q, 130E, 130E/158R, 130E/158R/393V, 130E/345Q/393V, 143S/271N, 143S, 143S/387N, 151L, 151L/158R/217K/343G/345Q/393V, 151L/206S/282N/337R/343D/345Q/398A, 151L/282N/393V, 151L/345Q/393V/398A, 151L/393V, 158R, 158R/393V, 202N, 206S, 206S/217K, 217K, 217K/337R/345Q/398A, 271N, 282N/393V, 337R/343G/345Q/398A, 343D, 343D/345Q/393V/398A, 393V, or 393V/398A, wherein the amino acid position(s) correspond to the amino acid sequence of SEQ ID NO: 158.

4. The recombinant polynucleotide of claim 1 , wherein said amino acid sequence of said encoded recombinant alpha galactosidase A comprises at least 91% sequence identity to SEQ ID NO: 158.

5. The recombinant polynucleotide of claim 1 , wherein said amino acid sequence of said encoded recombinant alpha galactosidase A comprises at least 95% sequence identity to SEQ ID NO: 158.

6. The recombinant polynucleotide of claim 1 , wherein said amino acid sequence of said encoded recombinant alpha galactosidase A comprises at least 99% sequence identity to SEQ ID NO: 158.

7. The recombinant polynucleotide of claim 1 , wherein said amino acid sequence of said encoded recombinant alpha galactosidase A comprises the polypeptide sequence of SEQ ID NO: 240, 276, 288, or 292.

8. The recombinant polynucleotide of claim 1 , wherein said encoded recombinant alpha galactosidase A is

(a) more thermostable than the alpha galactosidase A of SEQ ID NO:2;

(b) more stable at pH 7 than the alpha galactosidase A of SEQ ID NO:2;

(c) more stable at pH 4 than the alpha galactosidase A of SEQ ID NO:2;

(d) more stable to exposure to serum than the alpha galactosidase A of SEQ ID NO:2;

(e) more lysosomally stable than the alpha galactosidase A of SEQ ID NO:2; or

(f) more readily taken up by cells than the alpha galactosidase A of SEQ ID NO: 2.

9. The recombinant polynucleotide of claim 1 , wherein said encoded recombinant alpha galactosidase A depletes more globotriaosylceramide from cells than the alpha galactosidase A of SEQ ID NO: 2.

10. The recombinant polynucleotide of claim 1 , wherein said encoded recombinant alpha galactosidase A exhibits at least one improved property selected from: i) enhanced catalytic activity; ii) increased tolerance to pH 7; iii) increased tolerance to pH 4; iv) increased tolerance to serum; v) increased uptake into cells; vi) increased depletion of globotriaosylceramide from cells; vii) reduced immunogenicity; or a combination of any of i), ii), iii), iv), v), vi), and/or vii), as compared to a reference sequence of SEQ ID NO: 2.

11. The recombinant polynucleotide of claim 1 , wherein the polynucleotide sequence comprises SEQ ID NO: 239, 275, 287, or 291.

12. A host cell comprising the recombinant polynucleotide of claim 2 , wherein the host cell is an isolated bacterial cell, isolated yeast cell, isolated insect cell, isolated plant cell, or isolated mammalian cell.

13. The host cell of claim 12 , wherein the host cell is an isolated mammalian cell.

14. A host cell comprising the recombinant polynucleotide of claim 7 wherein the host cell is an isolated bacterial cell, isolated yeast cell, isolated insect cell, isolated plant cell, or isolated mammalian cell.

15. The host cell of claim 14 , wherein the host cell is an isolated mammalian cell.

16. A method of producing a recombinant alpha galactosidase A, comprising culturing said host cell of claim 12 , under conditions that said alpha galactosidase A encoded by said recombinant polynucleotide is produced.

17. The method of claim 16 , further comprising the step of recovering said alpha galactosidase A.

18. The method of claim 16 , further comprising the step of purifying said alpha galactosidase A.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Aug 21, 2024
From: INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT
To: CODEXIS, INC.
Reel/Frame 068361/0757 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 16, 2024
From: CODEXIS, INC.
To: CROSSWALK THERAPEUTICS, INC.
Reel/Frame 068660/0439 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 19, 2024
From: HALLOWS, WILLIAM CASEY; VALLIEU, KRISTEN JEAN; DELLAS, NIKKI; ZHU, YU; VIDUYA, JUDY VICTORIA ANTONIO; CHNG, CHINPING; SERO, ANTOINETTE; HUISMAN, GJALT W.; BOTHAM, RACHEL CATHLEEN; ALAOUI ISMAILI, MOULAY HICHAM
To: CODEXIS, INC.
Reel/Frame 068031/0308 →
SECURITY INTEREST Recorded Feb 15, 2024
From: CODEXIS, INC.
To: INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT
Reel/Frame 066600/0650 →
Continuity (3)
Division 16721102 · Dec 19, 2019
Provisional Application 62782553 · Dec 20, 2018
Related Publication 20220356458A1 · Nov 10, 2022
References Cited (239)
US 5179023A · Calhoun et al. · 1993 [cited by applicant]
US 5356804A · Desnick et al. · 1994 [cited by applicant]
US 5605793A · Stemmer · 1997 [cited by applicant]
US 5811238A · Stemmer et al. · 1998 [cited by applicant]
US 5830721A · Stemmer et al. · 1998 [cited by applicant]
US 5834252A · Stemmer et al. · 1998 [cited by applicant]
US 5837458A · Minshull et al. · 1998 [cited by applicant]
US 5928905A · Stemmer et al. · 1999 [cited by applicant]
US 6066626A · Yew et al. · 2000 [cited by applicant]
US 6083725A · Selden et al. · 2000 [cited by applicant]
US 6096548A · Stemmer · 2000 [cited by applicant]
US 6117679A · Stemmer · 2000 [cited by applicant]
US 6132970A · Stemmer · 2000 [cited by applicant]
US 6165793A · Stemmer · 2000 [cited by applicant]
US 6180406B1 · Stemmer · 2001 [cited by applicant]
US 6251674B1 · Tobin et al. · 2001 [cited by applicant]
US 6277638B1 · Stemmer · 2001 [cited by applicant]
US 6287861B1 · Stemmer et al. · 2001 [cited by applicant]
US 6287862B1 · Delcardayre et al. · 2001 [cited by applicant]
US 6291242B1 · Stemmer · 2001 [cited by applicant]
US 6297053B1 · Stemmer · 2001 [cited by applicant]
US 6303344B1 · Patten et al. · 2001 [cited by applicant]
US 6309883B1 · Minshull et al. · 2001 [cited by applicant]
US 6319713B1 · Patten et al. · 2001 [cited by applicant]
US 6319714B1 · Crameri et al. · 2001 [cited by applicant]
US 6323030B1 · Stemmer · 2001 [cited by applicant]
US 6326204B1 · delCardayre et al. · 2001 [cited by applicant]
US 6335160B1 · Patten et al. · 2002 [cited by applicant]
US 6335198B1 · delCardayre et al. · 2002 [cited by applicant]
US 6344356B1 · Stemmer · 2002 [cited by applicant]
US 6352859B1 · delCardayre et al. · 2002 [cited by applicant]
US 6355484B1 · Patten et al. · 2002 [cited by applicant]
US 6358740B1 · Patten et al. · 2002 [cited by applicant]
US 6358742B1 · Stemmer · 2002 [cited by applicant]
US 6365377B1 · Patten et al. · 2002 [cited by applicant]
US 6365408B1 · Stemmer · 2002 [cited by applicant]
US 6368861B1 · Crameri et al. · 2002 [cited by applicant]
US 6372497B1 · Stemmer · 2002 [cited by applicant]
US 6376246B1 · Crameri et al. · 2002 [cited by applicant]
US 6379964B1 · delCardayre et al. · 2002 [cited by applicant]
US 6387702B1 · Stemmer · 2002 [cited by applicant]
US 6391552B2 · Stemmer · 2002 [cited by applicant]
US 6391640B1 · Minshull et al. · 2002 [cited by applicant]
US 6395547B1 · Stemmer · 2002 [cited by applicant]
US 6406855B1 · Patten et al. · 2002 [cited by applicant]
US 6406910B1 · Patten et al. · 2002 [cited by applicant]
US 6413745B1 · Patten et al. · 2002 [cited by applicant]
US 6413774B1 · Stemmer · 2002 [cited by applicant]
US 6420175B1 · Stemmer · 2002 [cited by applicant]
US 6423542B1 · Crameri et al. · 2002 [cited by applicant]
US 6426224B1 · Crameri et al. · 2002 [cited by applicant]
US 6436675B1 · Welch et al. · 2002 [cited by applicant]
US 6444468B1 · Stemmer et al. · 2002 [cited by applicant]
US 6455253B1 · Patten et al. · 2002 [cited by applicant]
US 6479652B1 · Crameri et al. · 2002 [cited by applicant]
US 6482647B1 · Stemmer · 2002 [cited by applicant]
US 6489146B2 · Stemmer et al. · 2002 [cited by applicant]
US 6506602B1 · Stemmer · 2003 [cited by applicant]
US 6506603B1 · Stemmer · 2003 [cited by applicant]
US 6519065B1 · Colbourne et al. · 2003 [cited by applicant]
US 6521453B1 · Crameri et al. · 2003 [cited by applicant]
US 6528311B1 · delCardayre et al. · 2003 [cited by applicant]
US 6537746B2 · Arnold et al. · 2003 [cited by applicant]
US 6573098B1 · Stemmer · 2003 [cited by applicant]
US 6576467B1 · Stemmer · 2003 [cited by applicant]
US 6579678B1 · Patten et al. · 2003 [cited by applicant]
US 6586182B1 · Patten et al. · 2003 [cited by applicant]
US 6602986B1 · Stemmer et al. · 2003 [cited by applicant]
US 6613514B2 · Patten et al. · 2003 [cited by applicant]
US 6653072B1 · Patten et al. · 2003 [cited by applicant]
US 6716631B1 · delCardayre et al. · 2004 [cited by applicant]
US 6846968B1 · Erwin et al. · 2005 [cited by applicant]
US 6946296B2 · Patten et al. · 2005 [cited by applicant]
US 6961664B2 · Selifonov et al. · 2005 [cited by applicant]
US 6995017B1 · Stemmer · 2006 [cited by applicant]
US 7024312B1 · Selifonov et al. · 2006 [cited by applicant]
US 7058515B1 · Selifonov et al. · 2006 [cited by applicant]
US 7105297B2 · Minshull et al. · 2006 [cited by applicant]
US 7148054B2 · delCardayre et al. · 2006 [cited by applicant]
US 7288375B2 · Stemmer et al. · 2007 [cited by applicant]
US 7421347B2 · Selifonov et al. · 2008 [cited by applicant]
US 7430477B2 · Selifonov et al. · 2008 [cited by applicant]
US 7531341B1 · Vellard et al. · 2009 [cited by applicant]
US 7534564B2 · Patten et al. · 2009 [cited by applicant]
US 7534595B2 · Vellard et al. · 2009 [cited by applicant]
US 7560263B2 · Kakkis et al. · 2009 [cited by applicant]
US 7620500B2 · Mundorff et al. · 2009 [cited by applicant]
US 7620502B2 · Selifonov et al. · 2009 [cited by applicant]
US 7629170B2 · delCardayre et al. · 2009 [cited by applicant]
US 7702464B1 · Emig et al. · 2010 [cited by applicant]
US 7747391B2 · Gustafsson et al. · 2010 [cited by applicant]
US 7747393B2 · Fox · 2010 [cited by applicant]
US 7751986B2 · Gustafsson et al. · 2010 [cited by applicant]
US 7776598B2 · Patten et al. · 2010 [cited by applicant]
US 7783428B2 · Gustafsson et al. · 2010 [cited by applicant]
US 7795030B2 · Minshull et al. · 2010 [cited by applicant]
US 7833742B2 · Treco et al. · 2010 [cited by applicant]
US 7853410B2 · Selifonov et al. · 2010 [cited by applicant]
US 7868138B2 · Stemmer et al. · 2011 [cited by applicant]
US 7873499B2 · Selifonov et al. · 2011 [cited by applicant]
US 7904249B2 · Selifonov et al. · 2011 [cited by applicant]
US 7910545B2 · Meeker et al. · 2011 [cited by applicant]
US 7957912B2 · Selifonov et al. · 2011 [cited by applicant]
US 8383346B2 · Colbeck et al. · 2013 [cited by applicant]
US 8504498B2 · Fox · 2013 [cited by applicant]
US 8768871B2 · Fox · 2014 [cited by applicant]
US 8849575B2 · Gustafsson et al. · 2014 [cited by applicant]
US 8876066B1 · Richards · 2014 [cited by applicant]
US 9308281B2 · Guild et al. · 2016 [cited by applicant]
US 9593326B2 · Clark et al. · 2017 [cited by applicant]
US 9909113B2 · Calhoun et al. · 2018 [cited by applicant]
US 10973888B2 · Agard et al. · 2021 [cited by applicant]
US 11278600B2 · Agard et al. · 2022 [cited by applicant]
US 11427813B2 · Hallows et al. · 2022 [cited by applicant]
US 11497798B2 · Agard et al. · 2022 [cited by applicant]
US 20080220990A1 · Fox · 2008 [cited by applicant]
US 20090312196A1 · Colbeck et al. · 2009 [cited by applicant]
US 20110280856A1 · Selden et al. · 2011 [cited by applicant]
US 20120177722A1 · Weiner et al. · 2012 [cited by applicant]
US 20120328592A1 · Shulman et al. · 2012 [cited by applicant]
US 20130039898A1 · Okhamafe et al. · 2013 [cited by applicant]
US 20140005057A1 · Clark et al. · 2014 [cited by applicant]
US 20140214391A1 · Cope · 2014 [cited by applicant]
US 20140221216A1 · Cope et al. · 2014 [cited by applicant]
US 20150050658A1 · Cho · 2015 [cited by applicant]
US 20150133307A1 · Zhang et al. · 2015 [cited by applicant]
US 20150134315A1 · Sarmiento et al. · 2015 [cited by applicant]
US 20170051267A1 · Calhoun · 2017 [cited by applicant]
US 20170216411A1 · Treco et al. · 2017 [cited by applicant]
US 20170360900A1 · Agard et al. · 2017 [cited by applicant]
US 20180148703A1 · Shulman et al. · 2018 [cited by applicant]
US 20190002890A1 · Martini et al. · 2019 [cited by applicant]
US 20190358302A1 · Gotschall · 2019 [cited by applicant]
US 20200199563A1 · Hallows et al. · 2020 [cited by applicant]
US 20200360489A1 · Agard et al. · 2020 [cited by applicant]
US 20200360490A1 · Agard et al. · 2020 [cited by applicant]
US 20200405826A1 · Agard et al. · 2020 [cited by applicant]
US 20210009984A1 · Jung et al. · 2021 [cited by applicant]
US 20210244804A1 · Agard et al. · 2021 [cited by applicant]
US 20210269787A1 · Hallows et al. · 2021 [cited by applicant]
JP 2001504324A · 2001 [cited by applicant]
JP 2013520986A · 2013 [cited by applicant]
WO 9522625A1 · 1995 [cited by applicant]
WO 9600787A1 · 1996 [cited by applicant]
WO 970078A1 · 1997 [cited by applicant]
WO 9735966A1 · 1997 [cited by applicant]
WO 9811206A2 · 1998 [cited by applicant]
WO 9827230A1 · 1998 [cited by applicant]
WO 200042651A1 · 2000 [cited by applicant]
WO 200175767A2 · 2001 [cited by applicant]
WO 2009152336A1 · 2009 [cited by applicant]
WO 2010144103A1 · 2010 [cited by applicant]
WO 2012170930A9 · 2012 [cited by applicant]
WO 2013156552A1 · 2013 [cited by applicant]
WO 2016105889A1 · 2016 [cited by applicant]
WO 2018132471A1 · 2018 [cited by applicant]
WO 2019125059A1 · 2019 [cited by applicant]
WO 2020132252A2 · 2020 [cited by applicant]
WO 2021026447A1 · 2021 [cited by applicant]
WO 2021173928A2 · 2021 [cited by applicant]
WO 2024042485A1 · 2024 [cited by applicant]
Goswami et al., “Gene Therapy Leaves a Vicious Cycle”, Front. Onc. 9:297, 2019, 25 pages (Year: 2019). [cited by examiner]
Singh et al., Curr. Protein Pept. Sci. 18:1-11, 2017 (Year: 2017). [cited by examiner]
Zhang et al., Structure 26:1474-1485, 2018 (Year: 2018). [cited by examiner]
UniProt Database Accession No. F7BKN6, Aug. 2017, 2 pages (Year: 2017). [cited by examiner]
Altschul, S., et al., “Basic local alignment search tool,” J. Mol. Biol., 215: 403-410 [1990]. [cited by applicant]
Altschul, S.F., et al., “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs,” Nucleic Acids Res., 25(17):3389-3402 [1997]. [cited by applicant]
Beaucage, S.L., et al., “Deoxynucleoside phosphoamidites-A new class of key intermediates for deoxypolynucleotide synthesis,” Tetrahedron Letters, 22(20): 1859-62 [1981]. [cited by applicant]
Black, M.E., et al., “Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy,” Proc Natl Acad Sci USA, 93:3525-3529 [1996]. [cited by applicant]
Botstein, D., et al., “Strategies and applications of in vitro mutagenesis,” Science, 229(4719):1193-1201 [1985]. [cited by applicant]
Caldwell, R.C., et al., “Mutagenic PCR,” PCR Methods Appl., 3:S136-S140 [1994]. [cited by applicant]
Carter, P., “Site-directed mutagenesis,” Biochem. J., 237:1-7 [1986]. [cited by applicant]
Christians, F.C., et al., “Directed evolution of thymidine kinase for AZT phosphorylation using DNA family shuffling,” Nat. Biotechnol., 17:259-264 [1999]. [cited by applicant]
Crameri, A., et al., “DNA shuffling of a family of genes from diverse species accelerates directed evolution”, Nature, 391:288-291 [1998]. [cited by applicant]
Crameri, A., et al., “Improved green fluorescent protein by molecular evolution using DNA shuffling, ”Nat. Biotechnol., 14(3):315-319 [1996]. [cited by applicant]
Crameri, A., et al., “Molecular evolution of an arsenate detoxification pathway by DNA shuffling,” Nat. Biotechnol., 15(5):436-438 [1997]. [cited by applicant]
Dale, S.J., et al., “Oligonucleotide-directed random mutagenesis using the phosphorothioate method,” Methods Mol. Biol., 57:369-74 [1996]. [cited by applicant]
Durant, B., et al., “Sex differences of urinary and kidneyglobotriaosylceramide and lyso-globotriaosylceramide inFabry mice,” J. Lipid Res., 52:1742-6 [2011]. [cited by applicant]
Guo, Z., et al., “3'-End-Forming Signals of Yeast mRNA,” Mol. Cell. Biol., 15(11):5983-5990 [1995]. [cited by applicant]
Henikoff, S.,et al., “Amino acid substitution matrices from protein blocks,” Proc. Natl. Acad. Sci., 89:10915-10919 [1992]. [cited by applicant]
Ikeda, K., et al., “Phenylalanine ammonia-lyase modified with polyethylene glycol: Potential therapeutic agent for phenylketonuria,” Amino Acids, 29:283-287 [2005]. [cited by applicant]
Kramer, B., et al., “Different base/base mismatches are corrected with different efficiencies by the methyl-directed DNA mismatch-repair system of [cited by applicant]
Ling, M., et al., “Approaches to DNA Mutagenesis:An Overview,” Anal. Biochem., 254:157-78 [1997]. [cited by applicant]
Matthes, H.W.D., et al., “Simultaneous rapid chemical synthesis of over one hundred oligonucleotides on a microscale,” EMBO J., 3(4):801-05 [1984]. [cited by applicant]
McIlvaine, T.C., “A Buffer Solution for Colorimetric Comparison,” J. Biol. Chem., 49:183-186 [1921]. [cited by applicant]
Minshull, J., et al., “Protein evolution by molecular breeding,” Curr. Op. Chem. Biol., 3(3):284-290 [1999]. [cited by applicant]
Nance, C.S., et al., “Later-Onset Fabry Disease; An Adult Variant Presenting With the Cramp-Fasciculation Syndrome,” Arch. Neurol., 63:453-457 [2006]. [cited by applicant]
Needleman, S., et al., “A general method applicable to the search for similarities in the amino acid sequence of two proteins,” J. Mol. Biol. 48:443-453 [1970]. [cited by applicant]
Pearson, W.R., “Improved tools for biological sequence comparison,” Proc. Nat'l. Acad. Sci. USA, 85:2444-2448 [1988]. [cited by applicant]
Provencal, P., et al., “Relative distribution of Gb3 isoforms/analogsin NOD/SCID/Fabry mice tissues determined by tandem mass spectrometry,” Bioanal., 8(17):1793-1807 [2016]. [cited by applicant]
Romanos, M.A., et al., “Foreign gene expression in yeast: a review,” Yeast 8:423-488 [1992]. [cited by applicant]
Schiffmann, R., “Fabry disease,” Pharm. Ther., 122:65-77 [2009]. [cited by applicant]
Smith, M., “In vitro mutagenesis,” Ann. Rev. Genet., 19:423-462 [1985]. [cited by applicant]
Smith, T., et al., “Comparison of Biosequences,” Adv. Appl. Math, 2:482-489 [1981]. [cited by applicant]
Stemmer, W., “DNA Shuffling by Random Fragmentation and Reassembly: In vitro Recombination for Molecular Evolution,” Proc. Natl. Acad. Sci. USA, 91:10747-10751 [1994]. [cited by applicant]
Stemmer, W.P.C., “Rapid evolution of a protein in vitro by DNA shuffling”, Nature, 370:389-391 [1994]. [cited by applicant]
Wang, R.Y., et al., “Lysosomal storage diseases: Diagnostic confirmation and management of presymptomatic individuals,” Genet. Med., 13:457-484 [2011]. [cited by applicant]
Wells, J.A., et al., “Cassette mutagenesis: an efficient method for generation of multiple mutations at defined sites,” Gene, 34:315-323 [1985]. [cited by applicant]
Yasuda, K., et al., “Efficient and rapid purification of recombinant human α-galactosidase A by affinity column chromatography,” Prot. Exp. Pur,. 37(2):499-506 [2004]. [cited by applicant]
Zhang, J-H., et al., “Directed evolution of a fucosidase from a galactosidase by DNA shuffling and screening ,” Proc. Nat. Acad. Sci., U.S.A., 94:4504-4509 [1997]. [cited by applicant]
Zhao, H., et al., “Molecular evolution by staggered extension process (StEP) in vitro recombination,” Nat. Biotechnol., 16:258-261 [1998]. [cited by applicant]
UniProt Accession No. P06280 dated Dec. 5, 2018. [cited by applicant]
Southwood, S., et al., “Several Common HLA-DR Types Share Largely Overlapping Peptide Binding Repertoires,” J. Immunol., 160:3363-3373 [1998]. [cited by applicant]
Vita, R., et al., “The Immune Epitope Database 2.0,” Nucl. Acids Res., 38(Database issue):D854-62 [2010]. [cited by applicant]
UniProt Database Accession No. F1PFDO dated May 3, 2011. [cited by applicant]
UniProt Database Accession No. J3S8S8 dated Oct. 31, 2012. [cited by applicant]
UniProt Database Accession No. G1LPQ5 dated Oct. 19, 2011. [cited by applicant]
Guce, A.I., et al., “Catalytic Mechanism of Human Alpha-Galactosidase”, J. Biological Chemistry, 285(6):3625-3634 [2010]. [cited by applicant]
GenBank Accession No. AAP36507.1 dated May 13, 2003. [cited by applicant]
Sugawara, K., et al., “Structural characterization of mutant alpha-galactosidases causing Fabry disease,” J. Hum. Genet., 53(9):812-824 [2008]. [cited by applicant]
Qui, H., et al., “Impact of cysteine variants on the structure, activity, and stability of recombinant human alpha-galactosidase A,” The Protein Society, 24(9):1401-1411 [2015]. [cited by applicant]
Genbank Accession No. BAD96347 dated Jul. 26, 2016. [cited by applicant]
Ogawa et al., “Long-term inhibition of glycosphingolipid accumulation in Fabry model mice by a single systemic injection of AAV1 vector in the neonatal period”, Molecular Genetics and Metabolism, Academic Press, Amsterd… [cited by applicant]
Notice of Allowance for U.S. Appl. No. 17/196,858, mailed Nov. 15, 2024. [cited by applicant]
Notice of Allowance received for U.S. Appl. No. 18/656,340, mailed on Nov. 19, 2024. [cited by applicant]
Airaksinen, A et al., “Modified base compositions at degenerate positions of a mutagenic oligonucleotide enhance randomness in site-saturation mutagenesis,” Nucleic Acids Res., vol. 26; 576-581 (1998). [cited by applicant]
Hideyuki Kobayashi, Koibuchi Research Report, vol. 29, pp. 3-12 (2013). Concise explanation met by submission of attached English translation of Japanese Office Action for Japanese Application No. 2022-078184, mailed Ju… [cited by applicant]
International Preliminary Report on Patentability for PCT Patent Application No. PCT/US15/63329, mailed on Jul. 6, 2017. [cited by applicant]
International Preliminary Report on Patentability for PCT Patent Application No. PCT/US19/67493, mailed on Jul. 1, 2021. [cited by applicant]
International Preliminary Report on Patentability for PCT Patent Application No. PCT/US21/19811, mailed on Sep. 9, 2022, 7 pages. [cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US15/63329, mailed on Jun. 3, 2016, 11 pages. [cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US19/67493, mailed on Jun. 5, 2020, 11 pages. [cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US21/19811, mailed on Aug. 17, 2021, 10 pages. [cited by applicant]
Invitation to Pay Additional Fee received for PCT Patent Application No. PCT/US15/63329, mailed on Mar. 22, 2016, 2 pages. [cited by applicant]
Invitation to Pay Additional Fee received for PCT Patent Application No. PCT/US19/67493, mailed on Mar. 19, 2020, 2 pages. [cited by applicant]
Invitation to Pay Additional Fee received for PCT Patent Application No. PCT/US21/19811, mailed on Jun. 24, 2021, 2 pages. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 17/196,858, mailed Jul. 1, 2024. [cited by applicant]
Non-Final Office Action for U.S. Patent Application No. 16/721, 102, mailed on Nov. 5, 2021. [cited by applicant]
Notice of Allowance for U.S. Patent Application No. 16/721, 102, mailed on Apr. 22, 2022. [cited by applicant]
Notice of Allowance for U.S. Appl. No. 17/186,462, mailed on Jul. 8, 2024. [cited by applicant]
Notice to File Missing Parts for U.S. Appl. No. 18/656,340, mailed May 23, 2024. [cited by applicant]
Schultz, S.C et al., “Site Saturation Mutagenesis of Active Site Residues of ß-Lactamase,” Proteins Structure and Function, pp. 521-528, Plenum Press, New York (1987). [cited by applicant]
Siekierska, A et al., “a-Galactosidase Aggregation Is a Determinant of Pharmacological Chaperone Efficacy in Fabry Disease Mutants,” J. Biol. Chem., vol. 287; 28386-28397 (2012). [cited by applicant]
UniProt Database Accession No. A0A6P5ICW3, Jun. 2021, 2 pages (Year: 2021). [cited by applicant]
UniProt Database Accession No. A0A6P6IS94, Jun. 2021, 2 pages (Year: 2021). [cited by applicant]
UniProt Database Accession No. D5FGE4, Aug. 2017, 2 pages (Year: 2017). [cited by applicant]
Warren et al., UniProt Database, accession No. F715N7_CALJA, Jul. 2011. [cited by applicant]
Yoshikatsu Eto, Journal of the Japanese Society of Internal Medicine, vol. 98, No. 4, pp. 163-170 (2009). Concise explanation met by submission of attached English translation of Japanese Office Action for Japanese Appl… [cited by applicant]
Yoshimitsu, M et al., “Sequencing and characterization of the porcine a-galactosidase A gene: towards the generation of a porcine model for Fabry disease,” Mol. Biol. Rep., vol. 38; 3145-3152 (2011). [cited by applicant]